About us

COVID-19 Therapeutics Advice & Support Group (CTAG) is a subcommittee of the Joint Speciality Committee for Infectious Disease, acting as a formal advisory group to the Royal College of Physicians.

CTAG was established through discussion between Drugs and Therapeutics Committees, Area Prescribing Committees and specialists to provide advice and support in the management of COVID-19 whilst national guidelines evolve. 

Its intention is to bring together national advice from:

  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • National Institute for Health Research (NIHR)
  • Chief Medical Officers’ (CMO) offices
  • NHS England (NHSE)
  • National Institute for Health and Care Excellence (NICE)
  • Scottish Medicines Consortium (SMC)
  • All Wales Medicines Strategy Group (AWMSG)

CTAG is the parent group for two key subgroups, each with specialist membership from UK NHS provider sites. Each subgroup acts as a specialist panel for discussion and consensus on medicines to be used for patients with COVID-19 both within and outside of a clinical trial, whilst taking into account advice from key national stakeholders.

  • Antivirals; originally involving Infectious Diseases and Virology specialists from the High Consequence Infectious Diseases (HCID) Network, and subsequently expanded to include multidisciplinary representation from non-HCID NHS providers
  • Immunomodulatory; drawing membership from the Hemophagocytic lymphohistiocytosis Across Specialities Collaboration (HASC), a group already formed for management and research of HLH and have expanded remit to include hyper-inflammation associated with COVID-19

Additional subgroups may be considered for incorporation under the CTAG umbrella as the pandemic develops.

Download CTAG Terms of Reference

Download CTAG Members Declarations of Interest